Convertible Bonds Financing Program with a maximum nominal total amount of EGP 81 million


Image source: Reuters

(Boursier.com) – Farnext Announces the launch of a convertible bond financing program with a maximum nominal total of €81 million to increase cash flow and continue funding the pivotal Phase III clinical study for PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A (CMT1A).

Process characteristics

Funding of 35 tranches of OCEANE-BSA up to a total nominal amount of €81 million over 36 months, subject to customary terms, and for tranches 17 to 35, for approval of a specific mandate by the combined general meeting on 30 June 2021.
The issuance of the first tranche of OCEANE bonds with a total nominal amount of 5.5 million euros.
The maximum potential dilution resulting from 35 OCEANE-BSA for a shareholder owning 1% of the company’s share capital prior to financing will result in owning 0.38% of the share capital after withdrawing and transferring all OCEANEs and exercising the guarantees.


© 2021, Boursier.com


  • Gloria Holmes

    "Unapologetic pop culture trailblazer. Freelance troublemaker. Food guru. Alcohol fanatic. Gamer. Explorer. Thinker."

    Related Posts

    The cost of the Polestar 3 electric SUV is between 75,000 and 110,000 euros

    CEO Thomas Enginlath announced that the mid-size SUV Polestar 3, which will be launched this fall, will sell for between 75,000 and 110,000 euros. Speaking at the conference Europe Car…

    8 Marketing Conferences You Can’t Miss

    When you are in marketing, one of the most valuable assets you have in your network. The more people you know, the more customers you can reach. In other words,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *